FierceBiotechIT writer Ryan McBride reports that GlaxoSmithKline (GSK) launched a website that will allow authorized researchers the ability to use clinical study data on certain drugs from the London based pharma company. This launches GSK to the forefront of transparency in pharma. GSK has founded a group of independent reviewers to approve and deny researchers requests for use of information. It is estimated by senior vice president of science and innovation, Perry Nisen, that it will take approximately one month for the approval process for the board to take place. Once approved, the website has detail and sign-in features for researchers to safely get started. When researchers are logged in, they choose how they would like to use the information, and software can be purchased to help the researchers conduct tests. Further, a helpline will be provided for researchers to field additional questions. There are over 200 clinical studies dating back to 2007 currently on the website, and GSK wants to expand back to the year 2000. Will other pharma giants join GSK in online transparency? Read the full article here.
Single IRB – A Guide to the Common Rule sIRB Mandate
The sIRB requirement is active. Is your study affected?
Clinical Research Accelerated
You need high quality, timely board reviews so that you can get your study in the clinic.
Recent Posts
Pearl IRB 2023 Year-End Schedule
Snowball Sampling: Is it ethical to pay your study subjects to recruit participants on your behalf?
Improving Exempt Submissions: 7 Tips to Reduce Revision Requests
Common Rule Exceptions to the Use of a Single IRB for Multi-site Research Ends After May 11, 2023
Pearl IRB 2022 Year-End Schedule